000285631 001__ 285631
000285631 005__ 20260313130515.0
000285631 0247_ $$2doi$$a10.1161/SVIN.125.002055
000285631 0247_ $$2pmid$$apmid:41816510
000285631 0247_ $$2pmc$$apmc:PMC12959425
000285631 037__ $$aDZNE-2026-00270
000285631 041__ $$aEnglish
000285631 082__ $$a610
000285631 1001_ $$0P:(DE-2719)9003181$$aAsperger, Hannah$$b0$$eFirst author
000285631 245__ $$aImpact of Severe Prestroke Disability on Outcomes After Mechanical Thrombectomy: A Multicenter Analysis.
000285631 260__ $$aDallas, Tex.$$bAmerican Heart Association, National Center$$c2026
000285631 3367_ $$2DRIVER$$aarticle
000285631 3367_ $$2DataCite$$aOutput Types/Journal article
000285631 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773403343_16830
000285631 3367_ $$2BibTeX$$aARTICLE
000285631 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285631 3367_ $$00$$2EndNote$$aJournal Article
000285631 520__ $$aPatients with severe prestroke disability (PSD) remain underrepresented in mechanical thrombectomy studies, despite their growing relevance in aging populations. This study used data from the German Stroke Registry-Endovascular Treatment to evaluate functional recovery, mortality, and poststroke care outcomes in this high-risk population.We analyzed 9456 mechanical thrombectomy-treated patients with stroke from the German Stroke Registry-Endovascular Treatment (2015-2021), categorized by premorbid modified Rankin Scale (mRS): no PSD (mRS score, 0-1), moderate PSD (mPSD; mRS score, 2-3), and severe PSD (sPSD; mRS score, 4-5). Favorable outcomes were defined as an mRS score of 0 to 2 or return to baseline. Logistic regression adjusted for age, National Institutes of Health Stroke Scale, intravenous thrombolysis, reperfusion success, and sex was used to predict outcomes. A neural network subsequently explored feature importance.Among 9456 patients, 7387 had no PSD, 1648 mPSD, and 421 sPSD. Unadjusted 90-day outcomes showed increasing mortality with PSD severity and fewer favorable outcomes in both PSD groups. At 90 days, favorable outcomes occurred in 3020 patients without PSD (40.9%), 232 with mPSD (14.1%), and 85 with sPSD (20.2%). After adjustment, only mPSD was associated with lower odds of favorable outcomes, while both mPSD and sPSD remained independent predictors of higher mortality. Complication rates were similar across groups, except for higher vasospasm in patients without PSD. Including rebalanced sPSD samples in predictive models resulted in minor performance improvements but notable shifts in feature importance, with age and Alberta Stroke Program Early Computed Tomography Score emerging as key predictors, National Institutes of Health Stroke Scale decreasing in relevance, and factors such as local anesthesia and occlusion location becoming more prominent.Despite higher mortality, approximately a fifth of patients with PSD achieved favorable outcomes, suggesting that this group should not be routinely excluded from mechanical thrombectomy. Further studies should refine patient selection criteria and outcome definitions for this vulnerable population.URL: https://www.clinicaltrials.gov; Unique identifier: NCT03356392.
000285631 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285631 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x1
000285631 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285631 650_7 $$2Other$$adementia
000285631 650_7 $$2Other$$apatient discharge
000285631 650_7 $$2Other$$asample size
000285631 650_7 $$2Other$$astroke
000285631 650_7 $$2Other$$athrombectomy
000285631 7001_ $$0P:(DE-2719)2811949$$aBode, Felix$$b1$$udzne
000285631 7001_ $$0P:(DE-2719)9003076$$aEbrahimi, Taraneh$$b2
000285631 7001_ $$0P:(DE-2719)9000373$$aKindler, Christine$$b3
000285631 7001_ $$0P:(DE-HGF)0$$aLayer, Julia$$b4
000285631 7001_ $$00000-0002-8980-9337$$aMeißner, Julius Nicolai$$b5
000285631 7001_ $$00000-0002-5139-6848$$aNitsch, Louisa$$b6
000285631 7001_ $$0P:(DE-2719)9002936$$aShirvani, Omid$$b7
000285631 7001_ $$0P:(DE-2719)9002386$$aThielscher, Christian$$b8
000285631 7001_ $$0P:(DE-2719)9003408$$avon Danwitz, Niklas Michael$$b9$$udzne
000285631 7001_ $$00000-0001-5818-5392$$aWeller, Johannes$$b10
000285631 7001_ $$00000-0001-9093-8307$$aDorn, Franziska$$b11
000285631 7001_ $$0P:(DE-2719)2810273$$aPetzold, Gabor C$$b12
000285631 7001_ $$0P:(DE-2719)9000778$$aStösser, Sebastian$$b13$$udzne
000285631 7001_ $$aInvestigators, GSR-ET$$b14$$eCollaboration Author
000285631 773__ $$0PERI:(DE-600)3144224-9$$a10.1161/SVIN.125.002055$$gVol. 6, no. 1$$n1$$pe002055$$tStroke: vascular and interventional neurology$$v6$$x2694-5746$$y2026
000285631 8564_ $$uhttps://pub.dzne.de/record/285631/files/DZNE-2026-00270.pdf$$yRestricted
000285631 8564_ $$uhttps://pub.dzne.de/record/285631/files/DZNE-2026-00270.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003181$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285631 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811949$$aExternal Institute$$b1$$kExtern
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003076$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002936$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002386$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003408$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000285631 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810273$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000285631 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000778$$aExternal Institute$$b13$$kExtern
000285631 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285631 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x1
000285631 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-12$$wger
000285631 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000285631 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:03:42Z
000285631 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:03:42Z
000285631 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:03:42Z
000285631 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000285631 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-12
000285631 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000285631 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-12
000285631 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-12
000285631 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x0
000285631 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x1
000285631 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x2
000285631 9201_ $$0I:(DE-2719)1013038$$kAG Schultze$$lClinical Single Cell Omics (CSCO) / Systems Medicine$$x3
000285631 980__ $$ajournal
000285631 980__ $$aEDITORS
000285631 980__ $$aVDBINPRINT
000285631 980__ $$aI:(DE-2719)1011103
000285631 980__ $$aI:(DE-2719)1013020
000285631 980__ $$aI:(DE-2719)1011101
000285631 980__ $$aI:(DE-2719)1013038
000285631 980__ $$aUNRESTRICTED